<DOC>
	<DOCNO>NCT01221376</DOCNO>
	<brief_summary>The purpose study evaluate hematological , cytogenetic molecular response continuous-use Imatinib child CML Ph+ .</brief_summary>
	<brief_title>Phase II Study Safety Efficacy Evaluation Imatinib Mesylate Children With Chronic Myeloid Leukemia ( CML ) Philadelphia Chromosome-positive ( Ph+ )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Philadelphia Chromosome</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Diagnose : suspect CML ( hematology and/or myelogram and/or immunophenotyping and/or Leukocyte alkaline phosphatase [ LAP ] ) confirm , , cytogenetic and/or molecular biology . OBS : CML Ph+ newlydiagnose chronic accelerate phase ; resistant CML Ph+ Interferon α ( INFα ) , Hydroxyurea and/or lowdose ARAC chronic accelerate phase ; CML Ph+ cytogenetic relapse BMT , n't use Imatinib previously , chronic accelerate phase . 2 . Female patient childbearing age , pregnancy test ( blood βhCG ) perform treatment initiation . Effective contraception must use . Pregnant woman wo n't include . 3 . Karnofsky Lansky scale : ≥40 . 4 . Life expectation &gt; 8 week . 5 . Laboratory : renal function ( serum creatinine ≤ 1,5 x ULN and/or Clearance ≥70 ml/min/1,73m2 ) , hepatic function ( total bilirubin ≤ 1,5 x ULN , TGP &lt; 3 x ULN albumin &gt; 2 g/dl . 6 . CNS toxicity ≤ II 7 . Cardiac function : normal ejection fraction . 8 . Signed ICF child legal responsible . 1 . Patient receive tyrosine kinase inhibitor ( TKI ) . 2 . Pregnant patient breastfeeding . 3 . Patient consider incapable follow purpose treatment . 4 . Patients molecular relapse . 5 . Medications : Colony stimulating : administer least 1 week treatment . Anticonvulsants : Imatinib metabolize P450 enzyme , thereby subject receive drug activates P450 system . The anticonvulsant allow valproic acid benzodiazepine . Anticoagulants : The use warfarin ( Marevan ) allow . If anticoagulant need , lowmolecularweight heparin ( LMWH ) use . Avoid anticoagulant platelet &lt; 50000 . INFΑ 48h D1 . Hydroxyurea 24h D1 . ARAC dose &gt; 100 mg/m2 57 day , 14 day D1 . Anthracyclines , Mitoxantrone Etoposide 21 day D1 . Any chemotherapeutic agent 28 day D1 . Hematopoietic Cell Transplantation ( HCT ) 6 week D1 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>